Metaage EBIT per Share
The EBIT per Share of Metaage (6112.TW) as of Jul 25, 2026 is -0.72 TWD. In the previous year, EBIT per Share was 2.56 TWD — a change of -128.15% (lower).
Get this data via API
Financial Data API
EBIT per Share
-0.72TWD
YoY
-128.15%
Last updated:
EBIT per Share of Metaage is 2026 -0.72 TWD. EBIT per Share of Metaage was 2025 2.56 TWD. It decreases by -128.15% lower compared to the previous year.
Access this data via the Eulerpool API
Metaage Stock analysis
What does Metaage do? The Metaage Corp is an innovative company based in San Francisco that specializes in the development of technologies for cognitive aging research. The company was founded in 2016 by a team of experts from various fields, such as science, medicine, and technology.
The idea for the founding of Metaage Corp arose from the growing awareness of the impact of demographic change on society. The company aims to develop technologies that help older people maintain their cognitive health and make aging a positive experience.
The business model of Metaage Corp is based on a broad research and development strategy that includes the development of new products and technologies for use in various fields. The company is divided into several divisions, including the division for medical devices, the division for software applications, and the division for data analysis.
The medical devices of Metaage Corp are aimed at the health and well-being of older people. This includes a wide range of products, such as smart pillows that improve sleep and reduce the risk of falls, as well as wearable devices that enable continuous monitoring of health parameters, such as blood pressure and heart rate.
The software applications of Metaage Corp are aimed at improving the cognitive abilities of older people. This includes a range of games and exercises that activate the brain and increase cognitive performance in a playful way.
The data analysis department of Metaage Corp specializes in the collection and analysis of medical and health-related data. The company works closely with medical institutions and researchers to understand and analyze the effects of aging and age-related diseases on cognitive health.
The offering of Metaage Corp is complemented by a series of training sessions and courses aimed at medical professionals, researchers, and health organizations. The training aims to deepen understanding of the latest developments in aging research and contribute to the development of appropriate treatment options and therapies.
Metaage Corp has become a key player in aging research and is supported by numerous researchers and medical professionals. The company aims to meet the challenges of demographic change with innovative and advanced technologies and products and contribute to making the lives of older people more positive. Metaage is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Metaage stock
EBIT per Share of Metaage is -0.72 TWD in 2026.
Access this data via the Eulerpool API
Income Statement — Metaage
All Key Metrics — Metaage
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth